Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03710187 · ClinicalTrials.gov registry record · Phase 2
HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients
A Phase 2 study of Septic Shock, sponsored by University of Tennessee Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT03710187: Completed Phase 2 study of Septic Shock, sponsored by University of Tennessee Medical Center.
NCT03710187 is a Phase 2 study of Septic Shock that has completed, run by University of Tennessee Medical Center. The registered enrollment target is 84 participants, below the 5,056-participant average among 24 other Septic Shock trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03710187, a Phase 2 study of Septic Shock, has completed, sponsored by University of Tennessee Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be conducted as a single-center, prospective, open-label, randomized trial that will evaluate adult patients admitted with septic shock to the medical critical care unit (MCC). The objective of the study is to determine if the use of hydrocortisone plus fludrocortisone is associated with a faster resolution of shock (defined as 24 hours vasopressor free) when compared to the use of hydrocortisone alone in medical, critically ill septic shock patients.
Primary Outcome
Hours for patient to achieve 24 hours vasopressor free
Conditions Studied
Interventions
- DRUG Hydrocortisone
Study Locations (1)
Tennessee
- University of Tennessee Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 2 |
What the finished NCT03710187 record still lists
NCT03710187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 5,056-participant average among 24 other Septic Shock trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Septic Shock appearing as the primary indexed condition, and to 1 intervention - of which Hydrocortisone is the first listed.
NCT03710187 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03710187 about?
NCT03710187 is a clinical study titled "HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients". This study will be conducted as a single-center, prospective, open-label, randomized trial that will evaluate adult patients admitted with septic shock to the medical critical care unit (MCC). The objective of the study is to determine if the use of hydrocortisone plus fludrocortisone is associated ...
What is the current status of trial NCT03710187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2018-11-05. Estimated completion is 2019-09-27.
What conditions does trial NCT03710187 study?
This clinical trial studies the following conditions: Septic Shock.
What interventions are being tested in trial NCT03710187?
The interventions under investigation include: Hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT03710187?
This trial is sponsored by University of Tennessee Medical Center, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03710187 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03710187's enrollment target sits among peer trials
84 15th of 24 higher than 10 of 24 other Septic Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Septic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
-
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RECRUITING · Phase 3
-
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
RECRUITING · NA
-
Assessment for Implementation Methods in Sepsis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI